<DOC>
	<DOCNO>NCT01222468</DOCNO>
	<brief_summary>This study conduct study effect nabilone ( synthetic cannabinoid ) spasticity spinal cord injure persons.The study phase 2 , randomize , placebo-controlled crossover study . Each eligible subject participate 26 weeks.Subjects randomize receive either nabilone placebo phase 1 study . Study drug titrate 0.5mg daily maximum 3.0 mg daily first 11-week phase . Following 4-week washout period , subject crossed-over opposite arm another 11 week treatment period ( phase 2 ) .</brief_summary>
	<brief_title>Effect Cannabinoids Spasticity Neuropathic Pain Spinal Cord Injured Persons</brief_title>
	<detailed_description />
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Nabilone</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Spinal Cord Injury 12 month post injury C2T12 , ASIA AD , stable level injury moderate severe spasticity moderate severe neuropathic pain cognitive impairment spasticity medication unchanged least 30 day inadequate pain control stabilize dose either gabapentin pregabalin least 30 day botulinum toxin injection x 6 month significant cardiovascular disease major illness another body area history psychological disorder predisposition psychosis sensitivity cannabinoids severe liver disfunction history drug dependancy fix tendon contracture use cannabis past 30 day unwilling refrain smoke cannabis study pregnant nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Spasticity , Spinal Cord Injury</keyword>
</DOC>